Champions Oncolo Stock Price, News & Analysis

Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.

The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.

CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.

Champions Oncology (NASDAQ:CSBR) has formed a strategic collaboration with Turbine to enhance biopharma drug discovery workflows. The partnership combines Champions' multi-omic dataset with Turbine's virtual cell simulation platform, enabling researchers to conduct rapid in silico experiments with greater precision.

The collaboration integrates Champions' clinically annotated datasets with Turbine's simulation technology to reduce dependency on traditional lab methods. This integration aims to improve various aspects of drug discovery, from target identification to generating mechanistic insights.

The partnership leverages Champions' unique offering of deeply characterized samples combined with in vivo experimental results and clinical outcome data from the same patients, which Turbine identified as critical for training and validating simulations that predict treatment responses.

Champions Oncology (Nasdaq:CSBR) reported record-breaking financial results for Q3 fiscal 2025. Total revenue increased 42% to $17.0 million, with net income reaching $4.5 million and adjusted EBITDA of $5.2 million.

The company achieved several key milestones, including signing their first data licensing deal worth up to $8.0 million and improving operational efficiency. Core services business grew 4%, while gross profit reached $10.4 million with a 61% margin. Year-to-date performance showed 23% revenue growth to $44.6 million.

Cost reduction initiatives proved successful, with total costs decreasing by 14.1% to $12.5 million compared to the previous year. The company maintains a strong financial position with $3.2 million cash on hand and no debt, while research services margin improved from 35% to 48% year-over-year.

Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its third quarter fiscal 2025 financial results announcement for Tuesday, March 11, 2025, after market close.

The company will host a conference call at 4:30 P.M. EDT to discuss the results for the quarter ended January 31, 2025. Investors can join via phone using the access code 403045: Domestic (888-506-0062) or International (973-528-0011). A replay will be available through phone or the company's website investor section within 72 hours using passcode 52158.

Champions Oncology (NASDAQ:CSBR) has announced that seventeen abstracts have been accepted for presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, scheduled for April 25-30, 2025.

The presentations will showcase the company's research in multiple areas, including:

• Innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing
• AI-driven models using multi-omics datasets for patient outcome prediction

CEO Ronnie Morris highlighted that these presentations demonstrate how Champions' proprietary PDX bank and multi-omics dataset are advancing oncology research and supporting biopharma partners in accelerating drug development.

Champions Oncology (NASDAQ:CSBR) has announced significant enhancements to its bioanalytical services portfolio. The company has integrated multiple global Cytek Aurora flow cytometers to expand its capabilities and appointed Troy Tremaine, MBA, to lead Bioanalytical Commercial Strategy.

The addition of Cytek Aurora instruments strengthens Champions' existing spectral and conventional flow cytometry capabilities, enabling higher complexity spectral analysis. Troy Tremaine brings decades of commercial leadership experience in the preclinical and bioanalytical space across multiple therapeutic areas.

CEO Ronnie Morris expressed enthusiasm about these investments, highlighting how the Cytek Aurora instruments will enhance their competitiveness in this expanding market.

Champions Oncology (NASDAQ:CSBR) reported strong Q2 fiscal 2025 results with revenue increasing 17% to $13.5 million and adjusted EBITDA of $1.1 million. The company achieved net income of $730,000 and maintained a gross profit margin of 45%. First half 2025 performance showed 14% revenue growth to $27.6 million with net income of $2.1 million.

Total costs decreased by $771,000 (5.7%) compared to Q2 fiscal 2024. The company implemented operational improvements and efficiencies, leading to increased revenue conversion. Management projects annual revenue growth of 10-15%, supported by core business strength and new data platform revenue contributions. The company ended the quarter with $2.8 million cash and no debt.

Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its second quarter financial results announcement for Wednesday, December 11, 2024, after market close. The company will host a conference call at 4:30 P.M. EST to discuss the results for the quarter ended October 31, 2024. Investors can join via phone or access the replay through the company's website within 72 hours.

Champions Oncology (Nasdaq: CSBR) has announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing. This collaboration grants Champions Oncology exclusive rights to distribute and commercialize Weill Cornell Medicine's hematological patient-derived xenograft (PDX) models.

The PDX models were developed by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. Champions Oncology will serve as a repository to distribute these models to academic institutions worldwide, enhancing its position in the heme-oncology field.

This strategic partnership aligns with Champions Oncology's commitment to providing advanced preclinical oncology solutions and strengthens its portfolio in hematological research. The collaboration is expected to facilitate rapid and scalable access to these unique PDXs for both biopharma partners and academic institutions.